News and Trends 20 Sep 2022 CGT Catapult begins VR training to help ensure future workforce needs A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […] September 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Sep 2022 Adva Biotechnology is using artificial intelligence to manufacture cell therapies The manufacturing of cell therapies is highly complex, often depending on skilled manual labor. The Israeli startup Adva Biotechnology aims to use automation, optical sensing and artificial intelligence to remove the manual component from the process. Cancer cell therapies such as CAR-T immunotherapies have demonstrated enormous potential for treating forms of blood cancer. Currently available […] September 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […] September 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 12 Sep 2022 Orchestrating the evolving cell therapy supply chain In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […] September 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 6 Sep 2022 Meeting tech transfer challenges when manufacturing new biopharmaceuticals With increasingly complex therapeutics arriving almost monthly, efficient technology transfer between biopharma and manufacturers is more important than ever. Ken Forman, senior director of product strategy at IDBS, explains how good digital strategies can avoid common pitfalls in the tech transfer process. Biopharmaceutical lifecycle management (BPLM) is the key to delivering novel therapies and lifesaving […] September 6, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […] September 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Neukio Biotherapeutics completes financing round for development of cell therapy products Neukio Biotherapeutics, a Chinese company committed to developing novel cell therapy products, has closed $50 million in a series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital as new investors. Existing shareholders Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital have continued […] September 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 31 Aug 2022 How CDMOs keep pace with trends in advanced therapies Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO Lonza, sheds light on the latest trends in advanced therapies and how manufacturers are keeping up. In 2021, global funding going to cell and gene […] August 31, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Laverock Therapeutics created to develop next generation of programmable cell therapies Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Zelluna Immunotherapy announces investment from Takeda Ventures, Inc. Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic arm of Takeda. TVI investment joins Zelluna’s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email